Mid-Face Lift: Rejuvenate Your Look with MyMedicPlus — Cost, Top Hospitals & Success Rates | MyMedicPlus

The mid-face lift (also called a malar lift, cheek lift, or sub-periosteal mid-face lift) is a surgical rejuvenation procedure specifically targeting the central zone of the face — the area spanning from the lower eyelid margin to the nasolabial folds, encompassing the malar eminence (cheekbones), the suborbicularis oculi fat (SOOF) pad, and the descending cheek fat compartments. As the face ages, the midface undergoes characteristic changes including descent of the malar fat pad creating a 'double convexity' deformity with flattening of the anterior cheek, deepening of the nasojugal groove (tear trough) from orbital fat pseudoherniation, formation of malar bags from lymphatic stasis, and deepening of the nasolabial folds as the cheek soft tissue descends away from its youthful elevated position.

The mid-face lift directly addresses these anatomical changes by surgically repositioning the descended mid-face soft tissue — fat pads and the SMAS (superficial musculoaponeurotic system) layer — back to their original youthful position atop the malar eminence. This creates a natural volumetric restoration that differs fundamentally from surface skin tightening procedures, as the actual soft tissue scaffold is repositioned rather than merely the skin surface being pulled. The result is improved cheek projection, reduction of tear trough hollowing, smoothing of nasolabial folds, and restoration of the inverted-triangle of youthful facial beauty (broad upper face, tapered lower face).

Mid-face lift can be performed via several surgical approaches: transpalpebral (through an incision beneath the lower lashes, often combined with lower blepharoplasty), endoscopic (using small temporal and intraoral incisions with a camera-guided technique), or as part of a comprehensive facelift through preauricular incisions. The transpalpebral approach provides excellent access to the infraorbital and malar region but requires meticulous technique to avoid lower eyelid complications. The procedure is performed under general anaesthesia or intravenous sedation and takes 1.5–3 hours depending on whether adjunctive procedures are combined.

An ideal candidate typically presents in their 40s or 50s with midface descent as their predominant ageing concern, without significant jowling or neck laxity (which would be better addressed by full facelift). Pre-operative 3D imaging and careful anatomical assessment guide surgical planning.

The mid-face lift is specifically indicated for malar fat pad descent and cheek ptosis — the anatomical basis of the 'tired' or 'hollow' mid-face appearance that develops with age. It addresses the nasojugal groove (tear trough deformity) caused by the junction of descended cheek tissue with the fixed lower orbital rim, creating the characteristic 'negative vector' appearance where the cheeks appear deflated below prominent undereye bags. Malar bags — fluid-filled soft tissue irregularities at the cheek-eyelid junction — are reduced by the repositioning of tissue that compresses and smooths this area.

The procedure also improves early jowl formation arising from mid-face descent (in contrast to the mandibular jowling that requires facelift), partially effacing nasolabial folds by repositioning the cheek fat pad that contributes to their depth. In younger patients (30s–40s), mid-face lift is used for congenitally flat midfaces or early ageing presentation. When combined with lower blepharoplasty, it provides comprehensive rejuvenation of the periorbital and cheek complex, addressing all components of the under-eye and cheek ageing that injectable fillers alone cannot fully correct.

Ideal mid-face lift candidates are men and women aged 35–60 with primarily midface ageing concerns — malar descent, tear trough, nasolabial fold deepening — without significant skin excess requiring skin resection or significant neck/lower face laxity requiring full facelift. Patients with good underlying bone structure, particularly prominent malar eminences, achieve the most dramatic improvements as the elevated tissue has a strong skeletal foundation to rest upon. Adequate skin quality (moderate elasticity with some residual capacity for redraping) supports optimal outcomes.

Contraindications include patients with significant lower eyelid laxity (snap test abnormality) or negative vector orbits, where transpalpebral approaches carry elevated risk of ectropion (lower eyelid malposition) — these patients may require additional lid-tightening procedures (canthopexy or canthoplasty) at the time of surgery. Patients with prior lower blepharoplasty involving extensive fat removal are at higher risk of postoperative lower lid complications and require careful surgeon assessment. Active smoking within 4 weeks of surgery, poorly controlled diabetes, autoimmune conditions affecting wound healing, and anticoagulant use are standard surgical contraindications.

The transpalpebral sub-periosteal mid-face lift is the most direct and versatile approach, accessing the midface through an incision inside the lower lid (transconjunctival) or just beneath the lower lashes. The surgeon elevates the periosteum (bone lining) from the maxilla and zygomatic arch in the subperiosteal plane, releasing the retaining ligaments, and suspends the elevated soft tissue to the lateral orbital rim or temporal fascia using permanent sutures or absorbable suture suspensions. This approach is commonly combined with lower eyelid fat repositioning.

The endoscopic mid-face lift uses 3–4 small incisions in the scalp and intraoral sulcus (inside the upper lip). A camera and instruments are introduced to elevate the midface soft tissue in the subperiosteal plane under direct vision. This avoids conspicuous scars but requires significant technical expertise and specialised equipment. Thread lift procedures (using polydioxanone or barbed sutures) provide a minimally invasive but less durable alternative to surgical mid-face lifting — temporary improvement lasting 12–18 months is achievable. Non-surgical mid-face rejuvenation using volumetric filler (hyaluronic acid or Radiesse) to the malar region is the most common adjunct or alternative approach, providing immediate projection improvement without downtime.

The operating surgeon reviews the patient's complete medical history, current medications, and desired outcomes before finalising the surgical plan. Preoperative digital photography and computer simulation allow the surgeon and patient to align expectations and visualise potential results. Anaesthetic choice — general anaesthesia or intravenous sedation with local anaesthesia — is decided in consultation with the anaesthesiologist based on procedure complexity, patient health status, and patient preference. Postoperative care instructions, including wound care, activity restrictions, and follow-up scheduling, are provided in written form before surgery.

Surgical mid-face lift provides one of the most durable and anatomically natural rejuvenation outcomes in facial cosmetic surgery, addressing the root cause of midface ageing (tissue descent) rather than masking symptoms (surface skin tightening or volume filling). Published outcomes studies report that mid-face elevation with sub-periosteal techniques produces results lasting 7–10 years on average before revision consideration. The restoration of cheek projection and tear trough improvement significantly rejuvenates the periorbital region, with most patients and independent observers estimating a 10–15 year apparent age reduction.

Patient satisfaction rates for mid-face lifting procedures are high, with multiple prospective series reporting greater than 85% excellent or good satisfaction at 2-year follow-up. The procedure also enhances the results of simultaneous blepharoplasty by providing a volumetric cheek foundation that prevents lower eyelid hollowing — a common complication of isolated lower blepharoplasty that removes fat without repositioning descended cheek tissue.

The most significant specific risk of transpalpebral mid-face lift is lower eyelid malposition — ectropion (outward turning of the lower lid) or scleral show (excessive white showing below the cornea). This occurs in 1–5% of transpalpebral approaches and is more common in patients with pre-existing lower lid laxity, prior blepharoplasty, or negative vector orbits. Meticulous canthopexy (lateral lid suspension) and careful patient selection significantly reduce this risk; most cases resolve with massage and upward taping but severe cases require revision surgery.

Other complications include malar oedema (cheek swelling that can persist for 6–12 weeks), haematoma, infraorbital nerve injury causing temporary (and rarely permanent) numbness of the cheek and upper lip, and asymmetry. Temporary facial stiffness and an exaggerated appearance in the first 4–6 weeks before tissues settle is expected and should be discussed in counselling. Infection is rare when appropriate perioperative antibiotics are administered. Scar visibility depends on the approach used — transpalpebral scars heal to a fine line in the lower lid fold or inside the conjunctiva; endoscopic and temporal scars are hidden in the hairline.

The first 24–48 hours post-surgery involve the most significant swelling and bruising, particularly around the lower eyelids. Patients should sleep with head elevated at 30–45 degrees for the first 2 weeks to reduce oedema. Cold compresses applied gently around the orbital area (not pressure) help reduce swelling in the first 48 hours. Sutures are removed at 5–7 days; conjunctival sutures typically dissolve. Prescribed antibiotics and anti-inflammatory medications are taken for the first 5–7 days.

Most patients are comfortable returning to light social activities at 2–3 weeks, when the majority of bruising has resolved. Residual malar swelling is normal for 6–8 weeks and fully resolves by 3–4 months. Strenuous activity, heavy lifting, and bending forward are restricted for 4 weeks. Sun protection (SPF 50+ and hat) over the midface is essential for 3 months to prevent post-inflammatory hyperpigmentation. Follow-up visits at 1 week, 1 month, 3 months, and 1 year allow comprehensive monitoring of healing and long-term outcome assessment.

Mid-face lift surgery costs vary by technique, whether it is combined with additional procedures, and the surgeon's experience and location. In the United States, an isolated mid-face lift costs USD 5,000–10,000, while combining it with lower blepharoplasty raises the total to USD 8,000–15,000 including anaesthesia and facility fees. In the United Kingdom, isolated mid-face lift surgery at specialist centres costs GBP 4,000–8,000.

At internationally accredited plastic surgery centres in India, Thailand, South Korea, and Turkey — where fellowship-trained plastic surgeons perform high volumes of facial cosmetic surgery — mid-face lift procedures cost USD 2,000–5,000, with comprehensive combination procedures (mid-face lift, blepharoplasty, and rhinoplasty) available for USD 4,000–9,000. These savings of 50–70% make international facial surgery a compelling option for many patients from Western countries. South Korean clinics have particularly established reputations for facial cosmetic surgery expertise. JCI-accredited facilities in these countries operate to international standards of surgical safety and anaesthetic care.

Non-surgical alternatives for mid-face rejuvenation include volumetric filler injection with hyaluronic acid, Radiesse, or Sculptra to the malar eminence, tear trough, and nasolabial folds. While fillers cannot physically lift descended tissue, they provide an optical simulation of lifting through volumetric support, with results lasting 12–18 months. Liquid facelift protocols combining strategic filler placement across multiple facial compartments are popular as an interim or preparatory measure before surgical lifting.

Ultrasound-based lifting devices (Ultherapy) and radiofrequency technologies (Thermage, Morpheus8 RF microneedling) stimulate collagen production and provide moderate tightening of the SMAS layer non-surgically, achieving a 10–15% degree of tissue lifting that is suitable for early-stage midface laxity but not comparable to surgical elevation for moderate-to-significant descent. Full facelift surgery is the alternative for patients with concurrent lower face and neck ageing who would benefit from a more comprehensive tissue repositioning approach. The treating plastic surgeon can help determine which surgical or non-surgical approach best matches the patient's specific anatomical findings and goals.